- Market Capitalization, $K 63,786
- Shares Outstanding, K 52,716
- Annual Sales, $ 53,510 K
- Annual Income, $ -46,420 K
- 60-Month Beta 0.89
- Price/Sales 1.18
- Price/Cash Flow N/A
- Price/Book 1.16
|Period||Period Low||Period High||Performance|
| || |
-0.0800 (-6.25%)since 08/25/23
| || |
-0.2300 (-16.08%)since 06/27/23
| || |
-0.8200 (-40.59%)since 09/27/22
The pharma sector is poised to witness significant growth due to the widespread adoption of generic medicines and emerging technologies. Therefore, fundamentally strong pharma stocks Pfizer (PFE), Sanofi...
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
|3rd Resistance Point||1.2800|
|2nd Resistance Point||1.2600|
|1st Resistance Point||1.2300|
|1st Support Level||1.1800|
|2nd Support Level||1.1600|
|3rd Support Level||1.1300|